Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 7/20 | 0.70 |
| ▸ | MAOA | P21397 | 5/20 | 0.70 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.70 |
| ▸ | SDHA | P31040 | 2/20 | 0.70 |
| ▸ | LMNA | P02545 | 1/20 | 0.70 |
| ▸ | CALML3 | P27482 | 1/20 | 0.70 |
| ▸ | F10 | P00742 | 7/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6206760 | 1.00 | MAOB (0.70) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL6188560 | 0.92 | MAOB (0.71) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL6804192 | 0.92 | MAOB (0.71) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL6188751 | 0.92 | MAOB (0.70) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL6188755 | 0.92 | MAOB (0.70) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL5105329 | 0.90 | MAOB (0.68) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL5105331 | 0.90 | MAOB (0.68) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL6188369 | 0.90 | MAOB (0.68) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL6188370 | 0.90 | MAOB (0.68) | MAOBMAOAPTGS1SDHALMNA | |
| SCHEMBL14145200 | 0.89 | MAOB (0.66) | MAOBMAOAPTGS1SDHALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1546140-A2 | ANTIMICROBIAL OXAZOLIDINONES, PROCESS OF THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Wockhardt Limited (IN) | 2005-06-29 | — | — | EP | claimed |
| US-20040235900-A1 | Antimicrobial oxazolifinones with improved pharmacokinetic profile and safety advantages | WOCKHARDT LIMITED (IN) | 2004-11-25 | — | — | US | claimed |
| WO-2004007488-A2 | ANTIMICROBIAL OXAZOLIDINONES, PROCESS OF THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | WOCKHARDT LIMITED (IN) | 2004-01-22 | — | — | WO | claimed |
| EP-1546140-A2 | ANTIMICROBIAL OXAZOLIDINONES, PROCESS OF THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | Wockhardt Limited (IN) | 2005-06-29 | — | — | EP | disclosed |
| US-20040235900-A1 | Antimicrobial oxazolifinones with improved pharmacokinetic profile and safety advantages | WOCKHARDT LIMITED (IN) | 2004-11-25 | — | — | US | disclosed |
| WO-2004007488-A2 | ANTIMICROBIAL OXAZOLIDINONES, PROCESS OF THEIR PREPARATION, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | WOCKHARDT LIMITED (IN) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040235900-A1 | Antimicrobial oxazolifinones with improved pharmacokinetic profile and safety advantages | OXA1L, VIP, CYP51A1 | MAOB 1589/4885MAOA 2006/4885PTGS1 2160/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.